Nuvectra Corporation (NASDAQ: NVTR) and Senseonics Holdings (NASDAQ:SENS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitabiliy, institutional ownership, analyst recommendations, risk and valuation.
Earnings & Valuation
This table compares Nuvectra Corporation and Senseonics Holdings’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Nuvectra Corporation||$15.51 million||7.74||-$40.65 million||($4.31)||-2.69|
|Senseonics Holdings||$884,999.00||246.68||-$43.73 million||N/A||N/A|
Nuvectra Corporation has higher revenue and earnings than Senseonics Holdings.
This is a breakdown of current ratings and price targets for Nuvectra Corporation and Senseonics Holdings, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Nuvectra Corporation presently has a consensus price target of $13.00, suggesting a potential upside of 11.97%. Senseonics Holdings has a consensus price target of $4.50, suggesting a potential upside of 93.97%. Given Senseonics Holdings’ stronger consensus rating and higher probable upside, analysts clearly believe Senseonics Holdings is more favorable than Nuvectra Corporation.
Insider & Institutional Ownership
59.9% of Nuvectra Corporation shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Nuvectra Corporation and Senseonics Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
About Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company’s neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
About Senseonics Holdings
Senseonics Holdings, Inc. is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes. The Company’s Eversense system consists of components, such as a sensor, which is inserted subcutaneously in the upper arm by a healthcare provider; an external removable smart transmitter that receives, assesses and relays the data from the sensor and also provides vibratory alerts, and a mobile application that receives data from the transmitter and provides real-time glucose readings, alerts and other data on the user’s mobile device, such as a smartphone, Apple Watch or tablet.
Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.